Skip to main content

5 Result(s)

within Libo Yang MD, PhD Remove this filter

and

  1. No Access

    Article

    ASO Visual Abstract: Clinical Genetic Features and Neoadjuvant Chemotherapy Response in HER2-Low Breast Cancers—A Retrospective, Multicenter Cohort Study

    Libo Yang MD, PhD, Yuqiong Liu MS, Dandan Han MM, Sha Fu MD… in Annals of Surgical Oncology (2023)

  2. No Access

    Article

    ASO Author Reflections: Genetic Heterogeneity in HER2-Low Breast Cancers Reflects Different Treatment Responses

    Libo Yang MD, PhD in Annals of Surgical Oncology (2023)

  3. No Access

    Article

    Clinical Genetic Features and Neoadjuvant Chemotherapy Response in HER2-Low Breast Cancers: A Retrospective, Multicenter Cohort Study

    The objective of this work is to reveal differences in clinical and genetic features, as well as neoadjuvant chemotherapy (NAC) response, between HER2-low and HER2-zero or HER2-positive breast cancers.

    Libo Yang MD, PhD, Yuqiong Liu MS, DanDan Han MM, Sha Fu MD… in Annals of Surgical Oncology (2023)

  4. No Access

    Article

    Prognostic Score-Based Stratification Analysis Reveals Universal Benefits of Radiotherapy on Lowering the Risk of Ipsilateral Breast Event for Ductal Carcinoma In Situ Patients with Different Risk Levels

    We aimed to analyze the effects of radiotherapy (RT) on the incidence rate of ipsilateral breast event (IBE) in ductal carcinoma in situ (DCIS) patients with lumpectomy after being stratified by prognostic score.

    Libo Yang MD, PhD, Dongli Lu PhD, Yutian Lai MD, PhD… in Annals of Surgical Oncology (2021)

  5. No Access

    Article

    ASO Author Reflections: Omitting Radiotherapy for Ductal Carcinoma In Situ Patients with Lumpectomy: Now or in the Future?

    Libo Yang MD, PhD, Dongli Lu PhD, Hong Bu MD, PhD in Annals of Surgical Oncology (2020)